Nova Leah has developed SelectEvidence®, a cybersecurity compliance platform that manages cybersecurity throughout the lifetime of connected medical devices for manufacturers and healthcare providers. The platform offers a repeatable, traceable and auditable way to track risks for each device, highlight known vulnerabilities, recommend solutions and provide a feedback mechanism between manufacturers and hospitals. SelectEvidence® is designed to improve the security of connected medical devices, enhance patient safety and reduce associated regulatory costs. The platform has global deployments and a blue-chip customer base. The company intends to use the funds to continue to expand operations. Nova Leah is a spin-out from Dundalk Institute of Technology (DkIT) and is led by CEO Anita Finnegan; it is based in Dundalk, Ireland. Nova Leah develops SelectEvidence, a cybersecurity risk-management software built to help medical device manufacturers and healthcare providers implement and maintain device cybersecurity requirements. SelectEvidence was developed over a five-year R&D programme at Dundalk Institute of Technology. The company is initially targeting imaging and electro-medical device sectors in the US and maintains an office in Boston. Management is led by CEO Anita Finnegan and Lero researcher Dr Fergal McCaffery is a non-executive director. Nova Leah cites faster market deployment, reduced compliance costs and fewer recalls as key benefits and has early customers including Irish device manufacturer Orreco. Financially, the company rounded up €420,000 in funding including a €250,000 investment from Cosimo Venture Partners and a €172,000 Enterprise Ireland payment.

Total raised

$3M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2018